Literature DB >> 6294786

Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime.

H C Neu.   

Abstract

Cefotaxime is metabolized to 3-desacetylcefotaxime. The antibacterial activity of desacetylcefotaxime is four- to eightfold less than that of cefotaxime. The activity of desacetylcefotaxime is species- and strain-specific. Although desacetylcefotaxime is less active than cefotaxime, it is more active than cefazolin, cefamandole, or cefoxitin. Desacetylcefotaxime does not inhibit many strains of Morganella, most strains of Pseudomonas aeruginosa, some strains of Serratia marcescens, some strains of Providencia, and many strains of Bacteroides fragilis at clinically achievable concentrations. Cefotaxime and desacetylcefotaxime act synergistically against 72% of strains tested, and antagonism between the two compounds is seen only with strains of Morganella and Proteus vulgaris. The presence of the metabolite desacetylcefotaxime increases rather than decreases the activity of cefotaxime.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6294786     DOI: 10.1093/clinids/4.supplement_2.s374

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  14 in total

Review 1.  Pediatric antibiotic therapy in 1990s.

Authors:  S Chaudhary
Journal:  Indian J Pediatr       Date:  1995 Jan-Feb       Impact factor: 1.967

2.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

3.  Comparison of in vitro activity of cefotaxime and desacetylcefotaxime alone and in combination against 320 gram-negative clinical isolates.

Authors:  G Piédrola; I Galan; A Leyva; M C Maroto
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Comparison of agar dilution, microdilution, and disk elution methods for measuring the synergy of cefotaxime and its metabolite against anaerobes.

Authors:  J A Smith; D Henry; J Ngui-Yen; A Castell; S Coderre
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

Review 5.  The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.

Authors:  R N Jones
Journal:  Infection       Date:  1994       Impact factor: 3.553

6.  Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalis.

Authors:  D F Sahm; C N Baker; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

7.  Cefotaxime monotherapy of bacterial meningitis caused by gram-positive pathogens.

Authors:  H F Helwig
Journal:  Infection       Date:  1985       Impact factor: 3.553

8.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 9.  Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus.

Authors:  R N Jones
Journal:  Infection       Date:  1985       Impact factor: 3.553

10.  In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.

Authors:  K Oizumi; I Hayashi; S Aonuma; K Konno
Journal:  Drugs       Date:  1988       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.